RxDoctor Payments Data

John Fedor, MD

Cardiovascular Disease · Charlotte, NCNPI 1003827296

Payments from drug & device makers

$1,157in general payments, 2019–2025

Across 15 payments — averaging $77.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$524
  • Medical Device Business Services, Inc.$353
  • Biotronik Inc.$140
  • Boston Scientific$99
  • Catheter Precision Inc.$26
  • Pfizer$15

What the payments were for

  • Consulting fees$47541%
  • Travel & lodging$20217%
  • Food & beverage$48041%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic2$524
Medical Device Business Services, Inc.8$353
Biotronik Inc.2$140
Boston Scientific1$99
Catheter Precision Inc.1$26
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,157 in reported general payments places this provider in the 30th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$103,850
Medicare patients
1,753
Services billed
3,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban441$443,246
XareltoRivaroxaban62$70,521
EntrestoSacubitril/Valsartan14$23,488
Mexiletine Hcl73$7,300
Metoprolol Succinate353$5,168
Dofetilide14$4,265
Diltiazem 24hr Er (Cd)Diltiazem Hcl127$2,492
Propafenone Hcl ErPropafenone Hcl11$1,951
Potassium Chloride97$1,674
Pindolol12$1,387
Flecainide Acetate54$1,343
Amiodarone Hcl65$1,162
Rosuvastatin Calcium108$1,010
Midodrine Hcl16$932
Carvedilol99$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$443,246441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →